MedWatch

Orphazyme-founder on IPO: Now we can take the company all the way

According to co-founder and CEO in Orphazyme, Anders Hinsby, an IPO gives the Danish biotech company a chance to take its products through the last development phase towards a drug approval.

Foto: Henriette Dan Bonde/PR-foto

The future looks promising for the biotech company Orphazyme that will soon go public on the Danish stock exchange. 

This is according to co-founder and CEO in Orphazyme Anders Hinsby, who earlier this week met the press for the first time as the head of a soon-to-be publicly listed company.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier